


CLICK-BIO

SPLITTERA Platform

Split Intein mediated Protein Ligation



SPLITTERA

Split-intein site-specific conjugation platform

for
functionalization of any
Ab format, proteins,
VLPs



Business Model

- Technology evaluation agreement
- Joint development agreement
- R&D license
- Commercial license



Intellectual property

- SPLITTERA technology
- Fully owned and patented (WO2013/045632)



Universal

- Compatible with **any expression host**



Fast and simple

- **Efficient and highly specific**
- **Only a reducing agent is needed to trigger conjugation, no other external cofactors**
- **Cost-effective**



Versatile

- **Any recombinant protein**, no limit in type, size or structure
- **Any payload**: fluorophores, peptides, toxins
- Ideal for the creation of **libraries in antibody-based** clinical programs



Additional features

- **Site-specific** protein conjugation through the formation of **peptide bonds** *in vitro* or *in vivo*.
- Modification of a protein with **different payloads** thanks to SPLITTERA orthogonal inteins
- **Minimum scar**
- Protein **features are maintained**
- Inteins do not remain in the final product
- **In vivo** applications


CLICK-BIO

SPLITTERA Platform

BIOCONJUGATION – SITE SPECIFIC MODIFICATION OF PROTEINS

Functionalization of any protein with the desired payload (toxin, fluorescent or colorimetric probes, chemical compound, peptides, proteins, IgG derivatives, etc.).


Example: ADC DAR 4



- 1** Fusion of the N-terminal domain of the Split intein (Int^N) to the C-terminus of the antibody's heavy chain (HC) and / or light chain (LC)
- 2** Fusion of the C-terminal domain of the Split intein (Int^C) to the desired payload to be bound to the antibody
- 3** Intein specific ligation reaction (trans-splicing)
- 4** New peptide bonds are formed that covalently bind the payloads to the antibody

VERSATILE TOOL KIT


SPLITTERA 4 orthogonal split-inteins allow to incorporate different payloads on the same protein in one-step reaction.



Other formats of bispecific antibodies



Full-length bispecific antibodies



Technology for the generation of libraries of different bispecific antibody formats, allowing a fast evaluation of high numbers of candidates.